PA8502901A1 - Tratamiento de combinacion con il-1ra y compuestos que inhiben el procesamiento y la liberacion de il-1 - Google Patents
Tratamiento de combinacion con il-1ra y compuestos que inhiben el procesamiento y la liberacion de il-1Info
- Publication number
- PA8502901A1 PA8502901A1 PA20008502901A PA8502901A PA8502901A1 PA 8502901 A1 PA8502901 A1 PA 8502901A1 PA 20008502901 A PA20008502901 A PA 20008502901A PA 8502901 A PA8502901 A PA 8502901A PA 8502901 A1 PA8502901 A1 PA 8502901A1
- Authority
- PA
- Panama
- Prior art keywords
- release
- combination
- processing
- inhibit
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
EL INVENTO SE REFIERE A METODOS Y COMPOSICIONES PARA TRATAR Y PREVENIR ESTADOS MORBOSOS MEDIADOS POR LA INTERLEUQUINA 1 (Il-1). EN LOS METODOS Y LAS COMPOSICIONES SE USA UN POLIPÉPTIDO ANTAGONISTA DEL RECEPTOR DE LA INTERLEUQUINA 1 (Il-1ra), O UNA VARIANTE DEL MISMO, EN COMBINACION CON UN AGENTE NO ESTEROIDE QUE INHIBE EL PROCESAMIENTO Y LA LIBERACIÓN DE Il-1.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15401099P | 1999-09-14 | 1999-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8502901A1 true PA8502901A1 (es) | 2002-02-21 |
Family
ID=22549650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20008502901A PA8502901A1 (es) | 1999-09-14 | 2000-09-11 | Tratamiento de combinacion con il-1ra y compuestos que inhiben el procesamiento y la liberacion de il-1 |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1214087A1 (es) |
JP (1) | JP2003509378A (es) |
AR (1) | AR033650A1 (es) |
AU (1) | AU6464400A (es) |
BR (1) | BR0014003A (es) |
CA (1) | CA2383026A1 (es) |
CO (1) | CO5190701A1 (es) |
EC (1) | ECSP003652A (es) |
GT (1) | GT200000155A (es) |
PA (1) | PA8502901A1 (es) |
PE (1) | PE20010685A1 (es) |
TN (1) | TNSN00183A1 (es) |
WO (1) | WO2001019390A1 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10765747B2 (en) | 2004-04-02 | 2020-09-08 | Swedish Orphan Biovitrum Ab (Publ) | Methods of reducing aggregation of IL-1ra |
WO2008129288A2 (en) * | 2007-04-19 | 2008-10-30 | Boehringer Ingelheim International Gmbh | Disulfonamides useful in the treatment of inflammation |
PE20221627A1 (es) | 2015-02-16 | 2022-10-19 | Univ Queensland | Sulfonilureas y compuestos relacionados y uso de estos |
US11858922B2 (en) | 2016-02-16 | 2024-01-02 | The University Of Queensland | Sulfonylureas and related compounds and use of same |
ES2927777T3 (es) * | 2016-04-18 | 2022-11-10 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
WO2018136890A1 (en) | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
AU2017416068A1 (en) | 2017-05-24 | 2019-10-31 | The Provost, Fellows, Foundation Scholars, And Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Novel compounds and uses |
EP3634951B8 (en) | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
WO2019008029A1 (en) | 2017-07-07 | 2019-01-10 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
EP3978489A1 (en) | 2017-07-07 | 2022-04-06 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
MX2020000911A (es) | 2017-07-24 | 2020-09-10 | Novartis Ag Star | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp. |
US11518739B2 (en) | 2017-08-15 | 2022-12-06 | Inflazome Limited | Sulfonamide carboxamide compounds |
AU2018317798A1 (en) * | 2017-08-15 | 2020-02-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP |
US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
WO2019034696A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
EP3668842A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
WO2019068772A1 (en) | 2017-10-03 | 2019-04-11 | Inflazome Limited | NEW COMPOUNDS |
CA3078195A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
WO2019166629A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
WO2019166627A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
US11884645B2 (en) | 2018-03-02 | 2024-01-30 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
US11530200B2 (en) | 2018-03-02 | 2022-12-20 | Inflazome Limited | Compounds |
GB201806578D0 (en) * | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
EP3817817A1 (en) | 2018-07-03 | 2021-05-12 | Novartis AG | Nlrp modulators |
EP3823726A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche SA | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
JP2022505525A (ja) * | 2018-10-24 | 2022-01-14 | ノバルティス アーゲー | Nlrp活性に関連する状態を治療するための化合物及び組成物 |
EP3911631A4 (en) | 2019-01-14 | 2022-09-28 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
EP4157860A4 (en) * | 2020-05-25 | 2024-03-06 | Beijing Vdjbio Co., Ltd. | INTERLEUKIN-1 RECEPTOR ANTAGONIST AND FUSION PROTEIN WITH IT |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874424A (en) * | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
CN1127479C (zh) * | 1997-01-29 | 2003-11-12 | 辉瑞大药厂 | 磺酰脲衍生物及其在白介素-1活性的控制中的用途 |
US6015790A (en) * | 1997-10-06 | 2000-01-18 | Basf Aktiengesellschaft | Methods and compositions for treating rheumatoid arthritis |
EP0987552A3 (en) * | 1998-08-31 | 2000-06-07 | Pfizer Products Inc. | Diarylsulfonylurea binding proteins |
-
2000
- 2000-08-28 EP EP00951799A patent/EP1214087A1/en not_active Withdrawn
- 2000-08-28 CA CA002383026A patent/CA2383026A1/en not_active Abandoned
- 2000-08-28 WO PCT/IB2000/001192 patent/WO2001019390A1/en not_active Application Discontinuation
- 2000-08-28 BR BR0014003-1A patent/BR0014003A/pt not_active IP Right Cessation
- 2000-08-28 AU AU64644/00A patent/AU6464400A/en not_active Abandoned
- 2000-08-28 JP JP2001523022A patent/JP2003509378A/ja active Pending
- 2000-09-05 CO CO00066883A patent/CO5190701A1/es not_active Application Discontinuation
- 2000-09-11 PA PA20008502901A patent/PA8502901A1/es unknown
- 2000-09-12 PE PE2000000942A patent/PE20010685A1/es not_active Application Discontinuation
- 2000-09-12 AR ARP000104779A patent/AR033650A1/es not_active Application Discontinuation
- 2000-09-12 EC EC2000003652A patent/ECSP003652A/es unknown
- 2000-09-13 TN TNTNSN00183A patent/TNSN00183A1/fr unknown
- 2000-09-14 GT GT200000155A patent/GT200000155A/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR0014003A (pt) | 2002-05-21 |
EP1214087A1 (en) | 2002-06-19 |
AU6464400A (en) | 2001-04-17 |
AR033650A1 (es) | 2004-01-07 |
PE20010685A1 (es) | 2001-07-03 |
WO2001019390A1 (en) | 2001-03-22 |
GT200000155A (es) | 2002-03-08 |
JP2003509378A (ja) | 2003-03-11 |
CA2383026A1 (en) | 2001-03-22 |
ECSP003652A (es) | 2002-04-23 |
TNSN00183A1 (fr) | 2005-11-10 |
CO5190701A1 (es) | 2002-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8502901A1 (es) | Tratamiento de combinacion con il-1ra y compuestos que inhiben el procesamiento y la liberacion de il-1 | |
ES2146300T3 (es) | Utilizacion de composiciones antihelminticas para el tratamiento de infecciones causadas por anoplocephala perfoliata en equidos. | |
UY26296A1 (es) | Tratamiento medicamentoso del síndrome de piernas inquietas | |
AR045179A1 (es) | Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer | |
ES2188177T3 (es) | Composicion para la prevencion y/o el tratamiento de la osteoporosis y las alteraciones debidas al sindrome menopausico, que comprende propionil-l-carnitina y genisteina. | |
CO5160262A1 (es) | Formulaciones farmaceuticas de liberacion controlada | |
BR9612661A (pt) | Utilização de uma combinaç i de tensoatives agentes quelantes e óleos essenciais para desinfecção eficaz | |
BR0207961A (pt) | Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas | |
ECSP045407A (es) | Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf | |
AR028512A1 (es) | Composiciones antimicrobianas acidas para el tratamiento de alimentos y superficies que contactan alimentos y metodos para la utilizacion de estas | |
ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
AR012671A1 (es) | Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos | |
AR031473A1 (es) | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide | |
AR109263A2 (es) | Composición que comprende moxidectina | |
ES2157252T3 (es) | Aplicacion del riluzol en el tratamiento del neuro-sida. | |
ATE333896T1 (de) | Vaskularisierungsinhibitoren | |
BR0107628A (pt) | l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial | |
AR028730A1 (es) | Procedimiento para encontrar compuestos que son adecuados para el tratamiento y/o la profilaxis de la obesidad y utilizacion de dichos compuestos | |
PE20010642A1 (es) | Combinacion de pramipexol y clonidina para el tratamiento del sindrome de piernas inquietas | |
AR043660A1 (es) | El tratamiento de la enfermedad de alzheimer | |
UY28007A1 (es) | Tratamiento terapeutico | |
AR046402A1 (es) | Combinacion de principio activo que comprende un compuesto 2,5-dihidrobencenosulfonico y un modulador de los canales de potasio | |
CL2004001421A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor. | |
DE602004014787D1 (de) | Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln | |
AR047480A1 (es) | Composicion para la prevencion y/o tratamiento de enfermedades metabolicas oseas; proceso de preparacion y uso de esta composicion |